ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Amgen, Bristol-Myers Squibb and Hoffmann-La Roche side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Amgen×Bristol-Myers Squibb×Hoffmann-La Roche×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

AmgenBristol-Myers SquibbHoffmann-La Roche
studies on the registry1,0882,1842,744
open to participants now50155114
phase 3 studies under way508295
reach primary completion within a year356776
programswith a study of their own in two years2457+9 named only80+25 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAmgenBristol-Myers SquibbHoffmann-La Roche
Phase 1

Amgen: 8 of its 24 programs at phase 1

  1. AMG 691phase 1
  2. AMG 127phase 1
  3. etakafusp alfaphase 1
  4. Pan-KRAS Inhibitor AMG 410phase 1
  5. tambotatug pelitecanphase 1

and 3 more — sign in to see them all

33%

Bristol-Myers Squibb: 17 of its 57 programs at phase 1

  1. BMS-986454phase 1
  2. orevandrodegphase 1
  3. Actinium Ac 225 SSTR2-targeted Agent RYZ401phase 1
  4. BMS-985521phase 1
  5. BMS-986485phase 1

and 12 more — sign in to see them all

30%

Hoffmann-La Roche: 33 of its 80 programs at phase 1

  1. RAY121phase 1
  2. clesitamigphase 1
  3. P-CD19CD20-ALLO1 Cellsphase 1
  4. Anti-c-Met Antibody-drug Conjugate YL211phase 1
  5. AQUA07phase 1

and 28 more — sign in to see them all

41%
Phase 2

Amgen: 1 of its 24 programs at phase 2

  1. AMG 732phase 2
4%

Bristol-Myers Squibb: 17 of its 57 programs at phase 2

  1. irafamdastatphase 2
  2. moponetugphase 2
  3. delocamtenphase 2
  4. imzokitugphase 2
  5. Cyclophosphamidephase 2

and 12 more — sign in to see them all

30%

Hoffmann-La Roche: 18 of its 80 programs at phase 2

  1. tifeglipronphase 2
  2. autogene cevumeranphase 2
  3. hyaluronidase (human recombinant)phase 2
  4. RO7568282phase 2
  5. tambotatug pelitecanphase 2

and 13 more — sign in to see them all

23%
Phase 3

Amgen: 7 of its 24 programs at phase 3

  1. maridebart cafraglutidephase 3
  2. tarlatamabphase 3
  3. xaluritamigphase 3
  4. sotorasibphase 3
  5. olpasiranphase 3

and 2 more — sign in to see them all

29%

Bristol-Myers Squibb: 16 of its 57 programs at phase 3

  1. navlimetostatphase 3
  2. pumitamigphase 3
  3. adagrasibphase 3
  4. golcadomidephase 3
  5. zolacabtagene autoleucelphase 3

and 11 more — sign in to see them all

28%

Hoffmann-La Roche: 22 of its 80 programs at phase 3

  1. inavolisibphase 3
  2. afimkibartphase 3
  3. giredestrantphase 3
  4. divarasibphase 3
  5. glofitamabphase 3

and 17 more — sign in to see them all

28%
Approved, new studies

Amgen: 8 of its 24 programs at approved, new studies

  1. inebilizumabapproved, new study
  2. blinatumomabapproved, new study
  3. apremilastapproved, new study
  4. evolocumabapproved, new study
  5. romiplostimapproved, new study

and 3 more — sign in to see them all

33%

Bristol-Myers Squibb: 7 of its 57 programs at approved, new studies

  1. xanomelineapproved, new study
  2. trospiumapproved, new study
  3. deucravacitinibapproved, new study
  4. Nivolumabapproved, new study
  5. trospium chlorideapproved, new study

and 2 more — sign in to see them all

12%

Hoffmann-La Roche: 7 of its 80 programs at approved, new studies

  1. ocrelizumabapproved, new study
  2. Ranibizumabapproved, new study
  3. emicizumabapproved, new study
  4. faricimabapproved, new study
  5. Trastuzumabapproved, new study

and 2 more — sign in to see them all

9%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Amgen12 readouts · 3 phase 3·

Amgen, Dec ’26: 1 program whose next study reaches primary completion

  1. sotorasibphase 3 · Dec 17 · NCT04185883

Amgen, Jan ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. AMG 732phase 2 · Jan 6 · NCT06401044
  2. apremilastapproved, new study · Jan 10 · NCT07908641
  3. romosozumabapproved, new study · Jan 14 · NCT07811999
  4. maridebart cafraglutidephase 3 · Jan 21 · NCT06858839

Amgen, Feb ’27: 1 program whose next study reaches primary completion

  1. xaluritamigphase 3 · Feb 17 · NCT06613100

Amgen, Mar ’27: 1 program whose next study reaches primary completion

  1. AMG 691phase 1 · Mar 17 · NCT07745907

Amgen, Apr ’27: 2 programs whose next study reaches primary completion

  1. inebilizumabapproved, new study · Apr 13 · NCT05549258
  2. tarlatamabphase 3 · Apr 24 · NCT06598306

Amgen, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. evolocumabapproved, new study · May 29 · NCT05284747
·

Amgen, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. afliberceptphase 3 · Jul 31 · NCT07614776
··

Amgen, Oct ’27: 1 program whose next study reaches primary completion

  1. AMG 127phase 1 · Oct 2 · NCT07590193
Bristol-Myers Squibb22 readouts · 7 phase 3

Bristol-Myers Squibb, Nov ’26: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. trospiumapproved, new study · Nov 24 · NCT06585787
  2. xanomelineapproved, new study · Nov 24 · NCT06585787

Bristol-Myers Squibb, Dec ’26: 7 programs whose next study reaches primary completion, 1 in phase 3

  1. actinium AC-225 dotatatephase 3 · Dec 0 · NCT05477576
  2. navlimetostatphase 3 · Dec 5 · NCT07777133
  3. delocamtenphase 2 · Dec 14 · NCT06122779
  4. golcadomidephase 3 · Dec 14 · NCT07763418
  5. moponetugphase 2 · Dec 17 · NCT06268886

and 2 more — sign in to see them all

Bristol-Myers Squibb, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. mezigdomidephase 3 · Jan 10 · NCT05519085

Bristol-Myers Squibb, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. Actinium Ac 225 SSTR2-targeted Agent RYZ401phase 1 · Feb 0 · NCT07165132
  2. Nivolumabapproved, new study · Feb 5 · NCT06946797
  3. repotrectinibphase 3 · Feb 16 · NCT06140836

Bristol-Myers Squibb, Mar ’27: 1 program whose next study reaches primary completion

  1. trospium chlorideapproved, new study · Mar 29 · NCT07063342
·

Bristol-Myers Squibb, May ’27: 1 program whose next study reaches primary completion

  1. elranatamabphase 2 · May 31 · NCT06988488

Bristol-Myers Squibb, Jun ’27: 3 programs whose next study reaches primary completion

  1. BMS-986533phase 1 · Jun 1 · NCT07629999
  2. BMS-986485phase 1 · Jun 8 · NCT07887763
  3. BMS-986454phase 1 · Jun 28 · NCT07171983

Bristol-Myers Squibb, Jul ’27: 1 program whose next study reaches primary completion

  1. zolacabtagene autoleucelphase 3 · Jul 15 · NCT06220201

Bristol-Myers Squibb, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. atigotatugphase 3 · Aug 17 · NCT06646276

Bristol-Myers Squibb, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. dezandrodegphase 3 · Sep 12 · NCT06764485

Bristol-Myers Squibb, Oct ’27: 1 program whose next study reaches primary completion

  1. BMS-986488phase 1 · Oct 15 · NCT06764771
Hoffmann-La Roche27 readouts · 7 phase 3

Hoffmann-La Roche, Nov ’26: 1 program whose next study reaches primary completion

  1. divarasibphase 3 · Nov 30 · NCT04302025

Hoffmann-La Roche, Dec ’26: 4 programs whose next study reaches primary completion

  1. RG6496phase 1 · Dec 1 · NCT07246941
  2. tifeglipronphase 2 · Dec 7 · NCT06982131
  3. afimkibartphase 3 · Dec 31 · NCT05910528
  4. inavolisibphase 3 · Dec 31 · NCT03006172

Hoffmann-La Roche, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. faricimabapproved, new study · Jan 26 · NCT05224102

Hoffmann-La Roche, Feb ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. Ranibizumabapproved, new study · Feb 4 · NCT04657289
  2. cevostamabphase 3 · Feb 26 · NCT05535244

Hoffmann-La Roche, Mar ’27: 4 programs whose next study reaches primary completion

  1. pegozaferminphase 3 · Mar 2 · NCT07835243
  2. glofitamabphase 3 · Mar 22 · NCT06624085
  3. RAY121phase 1 · Mar 31 · NCT06371417
  4. RO7812653phase 1 · Mar 31 · NCT07234942

Hoffmann-La Roche, Apr ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. enicepatidephase 3 · Apr 8 · NCT07626515
  2. Crovalimabphase 3 · Apr 18 · NCT04432584
  3. baloxavirphase 3 · Apr 30 · NCT07827599

Hoffmann-La Roche, May ’27: 1 program whose next study reaches primary completion

  1. RO7806881phase 1 · May 11 · NCT07271693

Hoffmann-La Roche, Jun ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. fenebrutinibphase 3 · Jun 8 · NCT07161258
  2. DONQ52phase 2 · Jun 15 · NCT07239336
  3. RO7890597phase 1 · Jun 15 · NCT07797478
  4. astegolimabphase 3 · Jun 30 · NCT05878769

Hoffmann-La Roche, Jul ’27: 2 programs whose next study reaches primary completion

  1. giredestrantphase 3 · Jul 31 · NCT03332797
  2. trontinemabphase 3 · Jul 31 · NCT04639050

Hoffmann-La Roche, Aug ’27: 2 programs whose next study reaches primary completion

  1. RO7837195phase 2 · Aug 25 · NCT06979336
  2. bizrolertinibphase 3 · Aug 31 · NCT05593094

Hoffmann-La Roche, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. zemocimigphase 3 · Sep 23 · NCT07416526

Hoffmann-La Roche, Oct ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. mosunetuzumabphase 3 · Oct 1 · NCT05207670
  2. emicizumabapproved, new study · Oct 6 · NCT06998524
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 24, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Amgen

New programs 0

None

Reached a new phase 0

None

Study stopped 1

Primary completion later 5

Bristol-Myers Squibb

New programs 5

  • BMS-986548phase 2 · first study · Nov 10
  • BMS-986485phase 1 · first study · Oct 14
  • BMS-986553phase 1 · first study · Oct 8 · Lupus Nephritis
  • RYZ711phase 2 · first study · Oct 1 · Prostatic Neoplasms
  • BMS-986527phase 1 · first study · Sep 22 · Carcinoma, Renal Cell

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Hoffmann-La Roche

New programs 4

  • RO7836748phase 1 · first study · Oct 23
  • RO7821657phase 1 · first study · Oct 14
  • RO7965032phase 2 · first study · Sep 25 · Geographic Atrophy
  • RO7830698phase 2 · first study · Sep 11 · Pulmonary Disease, Chronic Obstructive

Reached a new phase 1

Study stopped 1

  • RO7763505phase 1 · terminated Nov 17 · none of its studies left running“The development of RO7763505 for coronary artery disease has been discontinued.” · NCT07495813

Primary completion later 11

Where they overlap

Conditions where at least two of them have programs: 47 in all. A program counts in each condition its studies name most.

ConditionAmgenBristol-Myers SquibbHoffmann-La Roche
Carcinoma, Non-Small-Cell Lungall three · compare here

Amgen in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. sotorasibphase 3
  2. Pan-KRAS Inhibitor AMG 410phase 1
  3. tambotatug pelitecanphase 1
  4. romiplostimapproved, new study

Their studies: Amgen’s studies of Carcinoma, Non-Small-Cell Lung in search

Bristol-Myers Squibb in Carcinoma, Non-Small-Cell Lung: 11 programs

  1. navlimetostatphase 3
  2. pumitamigphase 3
  3. adagrasibphase 3
  4. izalontamab brengitecanphase 3
  5. repotrectinibphase 3

and 6 more — sign in to see them all

Their studies: Bristol-Myers Squibb’s studies of Carcinoma, Non-Small-Cell Lung in search

Hoffmann-La Roche in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. divarasibphase 3
  2. tambotatug pelitecanphase 2
  3. AQUA07phase 1
  4. lorlatinibphase 1

Their studies: Hoffmann-La Roche’s studies of Carcinoma, Non-Small-Cell Lung in search

Small Cell Lung Carcinomaall three · compare here

Amgen in Small Cell Lung Carcinoma: 4 programs

  1. tarlatamabphase 3
  2. etakafusp alfaphase 1
  3. tambotatug pelitecanphase 1
  4. Zocilurtatug Pelitecanphase 1

Their studies: Amgen’s studies of Small Cell Lung Carcinoma in search

Bristol-Myers Squibb in Small Cell Lung Carcinoma: 5 programs

  1. pumitamigphase 3
  2. izalontamab brengitecanphase 3
  3. atigotatugphase 3
  4. BMS-986525phase 2
  5. atigotatugphase 2

Their studies: Bristol-Myers Squibb’s studies of Small Cell Lung Carcinoma in search

Neoplasmsall three · compare here

Amgen in Neoplasms: 2 programs

  1. tarlatamabphase 3
  2. teprotumumabapproved, new study

Their studies: Amgen’s studies of Neoplasms in search

Bristol-Myers Squibb in Neoplasms: 5 programs

  1. repotrectinibphase 3
  2. BMS-986488phase 1
  3. BMS-986500phase 1
  4. Digoxinphase 1
  5. relatlimabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Neoplasms in search

Hoffmann-La Roche in Neoplasms: 4 programs

  1. inavolisibphase 3
  2. lorlatinibphase 1
  3. Pan-RAS Inhibitor RG6505phase 1
  4. Trastuzumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Neoplasms in search

Colorectal Neoplasmsall three · compare here

Amgen in Colorectal Neoplasms: 2 programs

  1. sotorasibphase 3
  2. afliberceptphase 3

Their studies: Amgen’s studies of Colorectal Neoplasms in search

Bristol-Myers Squibb in Colorectal Neoplasms: 3 programs

  1. pumitamigphase 3
  2. adagrasibphase 3
  3. Nivolumabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Colorectal Neoplasms in search

Hoffmann-La Roche in Colorectal Neoplasms: 5 programs

  1. inavolisibphase 3
  2. divarasibphase 3
  3. autogene cevumeranphase 2
  4. Lead Pb 203-DOTAMphase 1
  5. Trastuzumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Colorectal Neoplasms in search

Prostatic Neoplasmsall three · compare here

Amgen in Prostatic Neoplasms: 2 programs

  1. tarlatamabphase 3
  2. xaluritamigphase 3

Their studies: Amgen’s studies of Prostatic Neoplasms in search

Bristol-Myers Squibb in Prostatic Neoplasms: 3 programs

  1. dezandrodegphase 3
  2. RYZ711phase 2
  3. orevandrodegphase 1

Their studies: Bristol-Myers Squibb’s studies of Prostatic Neoplasms in search

Hoffmann-La Roche in Prostatic Neoplasms: 3 programs

  1. inavolisibphase 3
  2. GDC-1261phase 2
  3. Immunoglobulin Gphase 1

Their studies: Hoffmann-La Roche’s studies of Prostatic Neoplasms in search

Arthritis, Rheumatoidall three · compare here

Amgen in Arthritis, Rheumatoid: 1 program

  1. dazodalibepphase 3

Their studies: Amgen’s studies of Arthritis, Rheumatoid in search

Bristol-Myers Squibb in Arthritis, Rheumatoid: 3 programs

  1. tocilizumabphase 3
  2. BMS-986528phase 2
  3. BMS-986454phase 1

Their studies: Bristol-Myers Squibb’s studies of Arthritis, Rheumatoid in search

Hoffmann-La Roche in Arthritis, Rheumatoid: 3 programs

  1. afimkibartphase 3
  2. fenebrutinibphase 3
  3. ocrelizumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Arthritis, Rheumatoid in search

Lupus Erythematosus, Systemicall three · compare here

Amgen in Lupus Erythematosus, Systemic: 1 program

  1. inebilizumabapproved, new study

Their studies: Amgen’s studies of Lupus Erythematosus, Systemic in search

Bristol-Myers Squibb in Lupus Erythematosus, Systemic: 3 programs

  1. zolacabtagene autoleucelphase 3
  2. obexelimabphase 3
  3. deucravacitinibapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Lupus Erythematosus, Systemic in search

Hoffmann-La Roche in Lupus Erythematosus, Systemic: 3 programs

  1. cevostamabphase 3
  2. fenebrutinibphase 3
  3. P-CD19CD20-ALLO1 Cellsphase 1

Their studies: Hoffmann-La Roche’s studies of Lupus Erythematosus, Systemic in search

Lymphoma, Non-Hodgkinall three · compare here

Amgen in Lymphoma, Non-Hodgkin: 2 programs

  1. afliberceptphase 3
  2. blinatumomabapproved, new study

Their studies: Amgen’s studies of Lymphoma, Non-Hodgkin in search

Bristol-Myers Squibb in Lymphoma, Non-Hodgkin: 3 programs

  1. golcadomidephase 3
  2. lisocabtagene maraleucelphase 3
  3. fludarabinephase 1

Their studies: Bristol-Myers Squibb’s studies of Lymphoma, Non-Hodgkin in search

Hoffmann-La Roche in Lymphoma, Non-Hodgkin: 2 programs

  1. glofitamabphase 3
  2. mosunetuzumabphase 3

Their studies: Hoffmann-La Roche’s studies of Lymphoma, Non-Hodgkin in search

Obesityall three · compare here

Amgen in Obesity: 1 program

  1. maridebart cafraglutidephase 3

Their studies: Amgen’s studies of Obesity in search

Bristol-Myers Squibb in Obesity: 1 program

  1. Digoxinphase 1

Their studies: Bristol-Myers Squibb’s studies of Obesity in search

Hoffmann-La Roche in Obesity: 5 programs

  1. enicepatidephase 3
  2. petrelintidephase 3
  3. emugrobartphase 3
  4. tifeglipronphase 2
  5. HM17321no phase

Their studies: Hoffmann-La Roche’s studies of Obesity in search

Lymphoma, B-Cellall three · compare here

Amgen in Lymphoma, B-Cell: 1 program

  1. blinatumomabapproved, new study

Their studies: Amgen’s studies of Lymphoma, B-Cell in search

Bristol-Myers Squibb in Lymphoma, B-Cell: 1 program

  1. golcadomidephase 3

Their studies: Bristol-Myers Squibb’s studies of Lymphoma, B-Cell in search

Hoffmann-La Roche in Lymphoma, B-Cell: 3 programs

  1. glofitamabphase 3
  2. mosunetuzumabphase 3
  3. bexobrutidegno phase

Their studies: Hoffmann-La Roche’s studies of Lymphoma, B-Cell in search

Neoplasm Metastasisall three · compare here

Amgen in Neoplasm Metastasis: 1 program

  1. WRN Inhibitor AMG 436phase 1

Their studies: Amgen’s studies of Neoplasm Metastasis in search

Bristol-Myers Squibb in Neoplasm Metastasis: 2 programs

  1. adagrasibphase 3
  2. repotrectinibphase 3

Their studies: Bristol-Myers Squibb’s studies of Neoplasm Metastasis in search

Hoffmann-La Roche in Neoplasm Metastasis: 2 programs

  1. inavolisibphase 3
  2. giredestrantphase 3

Their studies: Hoffmann-La Roche’s studies of Neoplasm Metastasis in search

Lymphoma, Large B-Cell, Diffuseall three · compare here

Amgen in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. blinatumomabapproved, new study

Their studies: Amgen’s studies of Lymphoma, Large B-Cell, Diffuse in search

Bristol-Myers Squibb in Lymphoma, Large B-Cell, Diffuse: 2 programs

  1. lisocabtagene maraleucelphase 3
  2. Cyclophosphamidephase 2

Their studies: Bristol-Myers Squibb’s studies of Lymphoma, Large B-Cell, Diffuse in search

Hoffmann-La Roche in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. glofitamabphase 3

Their studies: Hoffmann-La Roche’s studies of Lymphoma, Large B-Cell, Diffuse in search

COVID-19all three · compare here

Amgen in COVID-19: 1 program

  1. apremilastapproved, new study

Their studies: Amgen’s studies of COVID-19 in search

Bristol-Myers Squibb in COVID-19: 1 program

  1. tocilizumabphase 3

Their studies: Bristol-Myers Squibb’s studies of COVID-19 in search

Hoffmann-La Roche in COVID-19: 1 program

  1. astegolimabphase 3

Their studies: Hoffmann-La Roche’s studies of COVID-19 in search

Nasopharyngeal Carcinomaall three · compare here

Amgen in Nasopharyngeal Carcinoma: 1 program

  1. tambotatug pelitecanphase 1

Their studies: Amgen’s studies of Nasopharyngeal Carcinoma in search

Bristol-Myers Squibb in Nasopharyngeal Carcinoma: 1 program

  1. izalontamab brengitecanphase 3

Their studies: Bristol-Myers Squibb’s studies of Nasopharyngeal Carcinoma in search

Hoffmann-La Roche in Nasopharyngeal Carcinoma: 1 program

  1. tambotatug pelitecanphase 2

Their studies: Hoffmann-La Roche’s studies of Nasopharyngeal Carcinoma in search

Pancreatic Neoplasmsall three · compare here

Amgen in Pancreatic Neoplasms: 1 program

  1. tambotatug pelitecanphase 1

Their studies: Amgen’s studies of Pancreatic Neoplasms in search

Bristol-Myers Squibb in Pancreatic Neoplasms: 1 program

  1. navlimetostatphase 3

Their studies: Bristol-Myers Squibb’s studies of Pancreatic Neoplasms in search

Hoffmann-La Roche in Pancreatic Neoplasms: 1 program

  1. tambotatug pelitecanphase 2

Their studies: Hoffmann-La Roche’s studies of Pancreatic Neoplasms in search

Alzheimer Disease2 of 3 · compare here–

Bristol-Myers Squibb in Alzheimer Disease: 5 programs

  1. irafamdastatphase 2
  2. moponetugphase 2
  3. xanomelineapproved, new study
  4. trospiumapproved, new study
  5. trospium chlorideapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Alzheimer Disease in search

Hoffmann-La Roche in Alzheimer Disease: 5 programs

  1. trontinemabphase 3
  2. RO7568282phase 2
  3. nivegacetorphase 2
  4. RO7812653phase 1
  5. Immunoglobulin Gphase 1

Their studies: Hoffmann-La Roche’s studies of Alzheimer Disease in search

Breast Neoplasms2 of 3 · compare here–

Bristol-Myers Squibb in Breast Neoplasms: 4 programs

  1. pumitamigphase 3
  2. izalontamab brengitecanphase 3
  3. actinium AC-225 dotatatephase 3
  4. Cyclophosphamidephase 2

Their studies: Bristol-Myers Squibb’s studies of Breast Neoplasms in search

Hoffmann-La Roche in Breast Neoplasms: 6 programs

  1. inavolisibphase 3
  2. giredestrantphase 3
  3. bizrolertinibphase 3
  4. vustanaciclibphase 2
  5. GDC-0587phase 1

and 1 more — sign in to see them all

Their studies: Hoffmann-La Roche’s studies of Breast Neoplasms in search

Multiple Myeloma2 of 3 · compare here–

Bristol-Myers Squibb in Multiple Myeloma: 6 programs

  1. mezigdomidephase 3
  2. arlocabtagene autoleucelphase 3
  3. Cyclophosphamidephase 2
  4. elranatamabphase 2
  5. fludarabinephase 1

and 1 more — sign in to see them all

Their studies: Bristol-Myers Squibb’s studies of Multiple Myeloma in search

Hoffmann-La Roche in Multiple Myeloma: 4 programs

  1. cevostamabphase 3
  2. hyaluronidase (human recombinant)phase 2
  3. RO7851624phase 1
  4. RO7875913phase 1

Their studies: Hoffmann-La Roche’s studies of Multiple Myeloma in search

Macular Edema2 of 3 · compare here

Amgen in Macular Edema: 2 programs

  1. afliberceptphase 3
  2. teprotumumabapproved, new study

Their studies: Amgen’s studies of Macular Edema in search

–

Hoffmann-La Roche in Macular Edema: 6 programs

  1. vamikibartphase 3
  2. RO7446603phase 2
  3. RO7497372phase 1
  4. RO7823653phase 1
  5. Ranibizumabapproved, new study

and 1 more — sign in to see them all

Their studies: Hoffmann-La Roche’s studies of Macular Edema in search

Multiple Sclerosis2 of 3 · compare here–

Bristol-Myers Squibb in Multiple Sclerosis: 2 programs

  1. zolacabtagene autoleucelphase 3
  2. obexelimabphase 3

Their studies: Bristol-Myers Squibb’s studies of Multiple Sclerosis in search

Hoffmann-La Roche in Multiple Sclerosis: 4 programs

  1. fenebrutinibphase 3
  2. P-CD19CD20-ALLO1 Cellsphase 1
  3. RO7845860phase 1
  4. ocrelizumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Multiple Sclerosis in search

Carcinoma, Hepatocellular2 of 3 · compare here–

Bristol-Myers Squibb in Carcinoma, Hepatocellular: 4 programs

  1. pumitamigphase 3
  2. Actinium Ac 225 GPC3-targeted Peptide RYZ801phase 2
  3. Nivolumabapproved, new study
  4. relatlimabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Carcinoma, Hepatocellular in search

Hoffmann-La Roche in Carcinoma, Hepatocellular: 1 program

  1. codrituzumabphase 2

Their studies: Hoffmann-La Roche’s studies of Carcinoma, Hepatocellular in search

Diabetes Mellitus, Type 22 of 3 · compare here

Amgen in Diabetes Mellitus, Type 2: 2 programs

  1. maridebart cafraglutidephase 3
  2. AMG 127phase 1

Their studies: Amgen’s studies of Diabetes Mellitus, Type 2 in search

–

Hoffmann-La Roche in Diabetes Mellitus, Type 2: 3 programs

  1. enicepatidephase 3
  2. emugrobartphase 3
  3. tifeglipronphase 2

Their studies: Hoffmann-La Roche’s studies of Diabetes Mellitus, Type 2 in search

Leukemia, Lymphocytic, Chronic, B-Cell2 of 3 · compare here–

Bristol-Myers Squibb in Leukemia, Lymphocytic, Chronic, B-Cell: 3 programs

  1. lisocabtagene maraleucelphase 3
  2. Cyclophosphamidephase 2
  3. fludarabinephase 1

Their studies: Bristol-Myers Squibb’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

Hoffmann-La Roche in Leukemia, Lymphocytic, Chronic, B-Cell: 2 programs

  1. mosunetuzumabphase 3
  2. bexobrutidegno phase

Their studies: Hoffmann-La Roche’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

Macular Degeneration2 of 3 · compare here

Amgen in Macular Degeneration: 1 program

  1. afliberceptphase 3

Their studies: Amgen’s studies of Macular Degeneration in search

–

Hoffmann-La Roche in Macular Degeneration: 4 programs

  1. avacincaptad pegolphase 1
  2. pegcetacoplanphase 1
  3. Ranibizumabapproved, new study
  4. faricimabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Macular Degeneration in search

Lupus Nephritis2 of 3 · compare here–

Bristol-Myers Squibb in Lupus Nephritis: 2 programs

  1. zolacabtagene autoleucelphase 3
  2. BMS-986553phase 1

Their studies: Bristol-Myers Squibb’s studies of Lupus Nephritis in search

Hoffmann-La Roche in Lupus Nephritis: 2 programs

  1. mosunetuzumabphase 3
  2. ocrelizumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Lupus Nephritis in search

Lymphoma2 of 3 · compare here–

Bristol-Myers Squibb in Lymphoma: 3 programs

  1. lisocabtagene maraleucelphase 3
  2. repotrectinibphase 3
  3. fludarabinephase 1

Their studies: Bristol-Myers Squibb’s studies of Lymphoma in search

Hoffmann-La Roche in Lymphoma: 1 program

  1. glofitamabphase 3

Their studies: Hoffmann-La Roche’s studies of Lymphoma in search

Lymphoma, Follicular2 of 3 · compare here–

Bristol-Myers Squibb in Lymphoma, Follicular: 3 programs

  1. golcadomidephase 3
  2. lisocabtagene maraleucelphase 3
  3. repotrectinibphase 3

Their studies: Bristol-Myers Squibb’s studies of Lymphoma, Follicular in search

Hoffmann-La Roche in Lymphoma, Follicular: 1 program

  1. mosunetuzumabphase 3

Their studies: Hoffmann-La Roche’s studies of Lymphoma, Follicular in search

Renal Insufficiency2 of 3 · compare here

Amgen in Renal Insufficiency: 1 program

  1. olpasiranphase 3

Their studies: Amgen’s studies of Renal Insufficiency in search

–

Hoffmann-La Roche in Renal Insufficiency: 3 programs

  1. petrelintidephase 3
  2. tifeglipronphase 2
  3. lorlatinibphase 1

Their studies: Hoffmann-La Roche’s studies of Renal Insufficiency in search

Schizophrenia2 of 3 · compare here–

Bristol-Myers Squibb in Schizophrenia: 3 programs

  1. xanomelineapproved, new study
  2. trospiumapproved, new study
  3. trospium chlorideapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Schizophrenia in search

Hoffmann-La Roche in Schizophrenia: 1 program

  1. ralmitarontphase 2

Their studies: Hoffmann-La Roche’s studies of Schizophrenia in search

Anemia, Hemolytic, Autoimmune2 of 3 · compare here–

Bristol-Myers Squibb in Anemia, Hemolytic, Autoimmune: 2 programs

  1. zolacabtagene autoleucelphase 3
  2. obexelimabphase 3

Their studies: Bristol-Myers Squibb’s studies of Anemia, Hemolytic, Autoimmune in search

Hoffmann-La Roche in Anemia, Hemolytic, Autoimmune: 1 program

  1. pegcetacoplanphase 1

Their studies: Hoffmann-La Roche’s studies of Anemia, Hemolytic, Autoimmune in search

Atherosclerosis2 of 3 · compare here

Amgen in Atherosclerosis: 2 programs

  1. maridebart cafraglutidephase 3
  2. olpasiranphase 3

Their studies: Amgen’s studies of Atherosclerosis in search

–

Hoffmann-La Roche in Atherosclerosis: 1 program

  1. selnoflastphase 2

Their studies: Hoffmann-La Roche’s studies of Atherosclerosis in search

Colitis, Ulcerative2 of 3 · compare here–

Bristol-Myers Squibb in Colitis, Ulcerative: 1 program

  1. deucravacitinibapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Colitis, Ulcerative in search

Hoffmann-La Roche in Colitis, Ulcerative: 2 programs

  1. afimkibartphase 3
  2. RO7837195phase 2

Their studies: Hoffmann-La Roche’s studies of Colitis, Ulcerative in search

Melanoma2 of 3 · compare here–

Bristol-Myers Squibb in Melanoma: 2 programs

  1. Nivolumabapproved, new study
  2. relatlimabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Melanoma in search

Hoffmann-La Roche in Melanoma: 1 program

  1. autogene cevumeranphase 2

Their studies: Hoffmann-La Roche’s studies of Melanoma in search

Pulmonary Disease, Chronic Obstructive2 of 3 · compare here–

Bristol-Myers Squibb in Pulmonary Disease, Chronic Obstructive: 1 program

  1. trospium chlorideapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Pulmonary Disease, Chronic Obstructive in search

Hoffmann-La Roche in Pulmonary Disease, Chronic Obstructive: 2 programs

  1. astegolimabphase 3
  2. RO7830698phase 2

Their studies: Hoffmann-La Roche’s studies of Pulmonary Disease, Chronic Obstructive in search

Arthritis, Juvenile2 of 3 · compare here

Amgen in Arthritis, Juvenile: 1 program

  1. apremilastapproved, new study

Their studies: Amgen’s studies of Arthritis, Juvenile in search

Bristol-Myers Squibb in Arthritis, Juvenile: 1 program

  1. tocilizumabphase 3

Their studies: Bristol-Myers Squibb’s studies of Arthritis, Juvenile in search

–
Arthritis, Psoriatic2 of 3 · compare here

Amgen in Arthritis, Psoriatic: 1 program

  1. apremilastapproved, new study

Their studies: Amgen’s studies of Arthritis, Psoriatic in search

Bristol-Myers Squibb in Arthritis, Psoriatic: 1 program

  1. deucravacitinibapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Arthritis, Psoriatic in search

–
Asthma2 of 3 · compare here

Amgen in Asthma: 1 program

  1. AMG 691phase 1

Their studies: Amgen’s studies of Asthma in search

–

Hoffmann-La Roche in Asthma: 1 program

  1. astegolimabphase 3

Their studies: Hoffmann-La Roche’s studies of Asthma in search

Coronary Artery Disease2 of 3 · compare here

Amgen in Coronary Artery Disease: 1 program

  1. evolocumabapproved, new study

Their studies: Amgen’s studies of Coronary Artery Disease in search

–

Hoffmann-La Roche in Coronary Artery Disease: 1 program

  1. RO7763505phase 1

Their studies: Hoffmann-La Roche’s studies of Coronary Artery Disease in search

Crohn Disease2 of 3 · compare here–

Bristol-Myers Squibb in Crohn Disease: 1 program

  1. deucravacitinibapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Crohn Disease in search

Hoffmann-La Roche in Crohn Disease: 1 program

  1. afimkibartphase 3

Their studies: Hoffmann-La Roche’s studies of Crohn Disease in search

Esophageal Squamous Cell Carcinoma2 of 3 · compare here

Amgen in Esophageal Squamous Cell Carcinoma: 1 program

  1. tambotatug pelitecanphase 1

Their studies: Amgen’s studies of Esophageal Squamous Cell Carcinoma in search

–

Hoffmann-La Roche in Esophageal Squamous Cell Carcinoma: 1 program

  1. tambotatug pelitecanphase 2

Their studies: Hoffmann-La Roche’s studies of Esophageal Squamous Cell Carcinoma in search

Immunoglobulin G4-Related Disease2 of 3 · compare here

Amgen in Immunoglobulin G4-Related Disease: 1 program

  1. inebilizumabapproved, new study

Their studies: Amgen’s studies of Immunoglobulin G4-Related Disease in search

Bristol-Myers Squibb in Immunoglobulin G4-Related Disease: 1 program

  1. obexelimabphase 3

Their studies: Bristol-Myers Squibb’s studies of Immunoglobulin G4-Related Disease in search

–
Liver Diseases2 of 3 · compare here

Amgen in Liver Diseases: 1 program

  1. maridebart cafraglutidephase 3

Their studies: Amgen’s studies of Liver Diseases in search

Bristol-Myers Squibb in Liver Diseases: 1 program

  1. admilparantphase 3

Their studies: Bristol-Myers Squibb’s studies of Liver Diseases in search

–
Myasthenia Gravis2 of 3 · compare here

Amgen in Myasthenia Gravis: 1 program

  1. inebilizumabapproved, new study

Their studies: Amgen’s studies of Myasthenia Gravis in search

–

Hoffmann-La Roche in Myasthenia Gravis: 1 program

  1. hyaluronidase (human recombinant)phase 2

Their studies: Hoffmann-La Roche’s studies of Myasthenia Gravis in search

Precursor Cell Lymphoblastic Leukemia-Lymphoma2 of 3 · compare here

Amgen in Precursor Cell Lymphoblastic Leukemia-Lymphoma: 1 program

  1. blinatumomabapproved, new study

Their studies: Amgen’s studies of Precursor Cell Lymphoblastic Leukemia-Lymphoma in search

Bristol-Myers Squibb in Precursor Cell Lymphoblastic Leukemia-Lymphoma: 1 program

  1. fludarabinephase 1

Their studies: Bristol-Myers Squibb’s studies of Precursor Cell Lymphoblastic Leukemia-Lymphoma in search

–
Psoriasis2 of 3 · compare here

Amgen in Psoriasis: 1 program

  1. apremilastapproved, new study

Their studies: Amgen’s studies of Psoriasis in search

Bristol-Myers Squibb in Psoriasis: 1 program

  1. deucravacitinibapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Psoriasis in search

–
Retinal Vein Occlusion2 of 3 · compare here

Amgen in Retinal Vein Occlusion: 1 program

  1. afliberceptphase 3

Their studies: Amgen’s studies of Retinal Vein Occlusion in search

–

Hoffmann-La Roche in Retinal Vein Occlusion: 1 program

  1. Ranibizumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Retinal Vein Occlusion in search

Stomach Neoplasms2 of 3 · compare here–

Bristol-Myers Squibb in Stomach Neoplasms: 1 program

  1. relatlimabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Stomach Neoplasms in search

Hoffmann-La Roche in Stomach Neoplasms: 1 program

  1. Trastuzumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Stomach Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Amgen 17 of 24 · Bristol-Myers Squibb 32 of 57 · Hoffmann-La Roche 39 of 80 programs (50 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Bristol-Myers Squibb: 9, Hoffmann-La Roche: 25).